For the quarter ending 2026-03-31, ANTX had $33,546K increase in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -10,028 | -8,710 | -9,353 | -17,111 |
| Stock-based compensation expense | 1,460 | 1,400 | 801 | 4,045 |
| Net accretion of discount on investments | 81 | 117 | 211 | 742 |
| Prepaid expenses and other assets | 267 | -159 | -2,513 | 1,160 |
| Accounts payable | -405 | 795 | 113 | -1,204 |
| Accrued compensation | -1,805 | 674 | 545 | -477 |
| Accrued liabilities | -285 | -653 | -249 | -1,500 |
| Other current liabilities | -662 | 1,046 | -534 | -74 |
| Other non-current liabilities | - | 170 | - | - |
| Net cash used in operating activities | -12,073 | -5,236 | -6,375 | -18,223 |
| Purchases of investments | 2,703 | 8,326 | 3,890 | 33,973 |
| Maturities of investments | 10,993 | 15,500 | 10,000 | 49,000 |
| Net cash provided by investing activities | 8,290 | 7,174 | 6,110 | 15,027 |
| Proceeds from issuance of common stock in the 2026 private placement, net of placement agent fees and other offering costs | 21,894 | - | - | - |
| Proceeds from issuance of pre-funded warrants in the 2026 private placement, net of placement agent fees and other offering costs | 15,372 | - | - | - |
| Proceeds from issuance of common stock under the espp | 39 | 0 | 48 | 38 |
| Proceeds from exercise of stock options | 24 | 0 | 0 | 27 |
| Net cash provided by financing activities | 37,329 | 0 | 48 | 65 |
| Net increase (decrease) in cash and cash equivalents | 33,546 | 1,938 | -217 | -3,131 |
| Cash and cash equivalents at the beginning of the period | 19,941 | 18,003 | 21,351 | - |
| Cash and cash equivalents at the end of the period | 53,487 | 19,941 | 18,003 | - |
AN2 Therapeutics, Inc. (ANTX)
AN2 Therapeutics, Inc. (ANTX)